Hospital
Dignity Health
Dignity Health was paid $39.92M by Medicaid between Jan 2018 and Nov 2024, across 257 billing codes. Its largest line is 0450, Emergency room services — 33% of everything it billed.
33Billing provider infoDIGNITY HEALTH
RED BLUFF, CA 96080
RED BLUFF, CA 96080
33aNPI1083732853assigned 03/27/2007
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$39.92M
24GClaims698,782
24DCodes billed257
24AFirst – last monthJan 2018 – Nov 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 88,193 | $4.78M | |
| 2019 | 94,957 | $5.45M | |
| 2020 | 80,979 | $4.50M | |
| 2021 | 99,310 | $5.51M | |
| 2022 | 115,782 | $6.49M | |
| 2023 | 138,711 | $7.25M | |
| 2024incomplete | 80,850 | $5.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 33% | 54,654 | 47,169 | $13.37M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.6% | 13,670 | 11,997 | $2.64M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 4.8% | 13,032 | 11,304 | $1.90M |
| A9150 | Non-prescription drugs | 4.6% | 12,403 | 7,030 | $1.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.6% | 9,311 | 8,043 | $1.44M |
| 0762 | 3.2% | 1,085 | 796 | $1.30M | |
| 36415 | Collection of venous blood by venipuncture | 3.1% | 16,892 | 14,265 | $1.25M |
| 99199 | Unlisted special service, procedure or report | 2.1% | 13,914 | 11,655 | $851K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 3,684 | 3,547 | $812K |
| 80053 | Comprehensive metabolic panel | 2.0% | 44,105 | 38,920 | $801K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 1.8% | 4,823 | 3,172 | $716K |
| 93976 | 1.5% | 2,621 | 2,571 | $603K |
245 more codes
| 99284 | Emergency room visit (serious) | 1.4% | 2,488 | $561K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 7,771 | $458K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 3,730 | $452K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 8,503 | $419K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,485 | $387K |
| 0250 | <1% | 31,153 | $377K | |
| Z7502 | <1% | 9,730 | $365K | |
| A0425 | Ground mileage, per statute mile | <1% | 14,793 | $363K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,195 | $330K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,315 | $330K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,654 | $277K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,162 | $275K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,340 | $275K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,747 | $275K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 761 | $275K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 4,974 | $260K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,175 | $236K |
| 0750 | <1% | 164 | $235K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,541 | $224K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,042 | $220K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,535 | $218K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,227 | $192K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,427 | $186K |
| J3490 | Unclassified drugs | <1% | 22,159 | $175K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,663 | $158K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,882 | $156K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,177 | $149K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,226 | $143K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,724 | $138K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,380 | $134K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,849 | $134K |
| 99285 | Emergency room visit (most serious) | <1% | 672 | $121K |
| 73030 | <1% | 1,607 | $100K | |
| 73130 | <1% | 1,235 | $99K | |
| 73630 | <1% | 1,874 | $94K | |
| 76830 | Ultrasound, transvaginal | <1% | 891 | $94K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,615 | $90K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,233 | $89K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,297 | $86K |
| 80061 | Lipid panel | <1% | 5,900 | $85K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 415 | $85K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,872 | $85K |
| 73610 | <1% | 1,421 | $82K | |
| 87070 | <1% | 3,633 | $77K | |
| 81001 | <1% | 16,732 | $77K | |
| 93971 | <1% | 664 | $76K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,517 | $74K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,595 | $73K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,361 | $72K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 122 | $72K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,039 | $71K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,876 | $70K |
| 99201 | <1% | 238 | $69K | |
| 0360 | <1% | 47 | $67K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,522 | $64K |
| 73110 | <1% | 864 | $64K | |
| 84703 | <1% | 2,770 | $62K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,462 | $58K |
| 85027 | <1% | 7,185 | $56K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,397 | $56K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,936 | $55K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 253 | $53K |
| 73562 | <1% | 777 | $50K | |
| 0949 | <1% | 699 | $49K | |
| 10060 | <1% | 235 | $46K | |
| 81003 | <1% | 9,110 | $46K | |
| 86803 | <1% | 2,007 | $45K | |
| 76536 | <1% | 375 | $40K | |
| 72110 | <1% | 423 | $36K | |
| 84484 | <1% | 9,891 | $36K | |
| 29125 | <1% | 219 | $34K | |
| 84439 | <1% | 3,287 | $33K | |
| 12001 | <1% | 164 | $33K | |
| 86850 | <1% | 3,415 | $31K | |
| 83880 | <1% | 3,196 | $30K | |
| 82962 | <1% | 3,620 | $29K | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 615 | $28K |
| 74018 | <1% | 702 | $28K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,776 | $28K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,758 | $28K |
| 87340 | <1% | 1,675 | $26K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,094 | $26K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 54 | $25K |
| 87077 | <1% | 3,042 | $24K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $24K |
| 87186 | <1% | 4,024 | $23K | |
| 83735 | <1% | 4,886 | $23K | |
| 86762 | <1% | 1,464 | $21K | |
| 76801 | <1% | 454 | $20K | |
| 83690 | <1% | 10,190 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,396 | $20K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 382 | $18K |
| 87040 | <1% | 3,989 | $18K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 54 | $18K |
| 86141 | <1% | 2,446 | $18K | |
| 84702 | <1% | 1,343 | $17K | |
| 73564 | <1% | 354 | $17K | |
| 73140 | <1% | 249 | $17K | |
| 83605 | <1% | 4,998 | $16K | |
| Z9725 | <1% | 336 | $14K | |
| 87631 | <1% | 397 | $14K | |
| 86592 | <1% | 2,296 | $14K | |
| 82746 | <1% | 624 | $14K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 498 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 338 | $13K |
| 73502 | <1% | 296 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,774 | $13K |
| 86900 | <1% | 3,575 | $13K | |
| 0720 | <1% | 225 | $12K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 410 | $12K |
| 76770 | <1% | 94 | $12K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 804 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 172 | $12K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,671 | $11K |
| 90715 | <1% | 1,083 | $11K | |
| 76641 | <1% | 75 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 359 | $11K |
| 86901 | <1% | 3,574 | $11K | |
| 72100 | <1% | 189 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,439 | $10K |
| 82607 | <1% | 651 | $10K | |
| 84145 | <1% | 1,459 | $10K | |
| 71250 | <1% | 29 | $9K | |
| 85610 | <1% | 4,298 | $9K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 198 | $9K |
| 99070 | <1% | 446 | $9K | |
| 85730 | <1% | 2,417 | $8K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,462 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,023 | $8K |
| 82728 | <1% | 560 | $8K | |
| 97802 | <1% | 44 | $7K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 17 | $7K |
| 87205 | <1% | 1,842 | $7K | |
| Z7610 | <1% | 1,402 | $7K | |
| 73080 | <1% | 171 | $7K | |
| A9270 | Non-covered item or service | <1% | 2,263 | $7K |
| 70498 | <1% | 130 | $6K | |
| 86787 | <1% | 646 | $6K | |
| 87075 | <1% | 689 | $6K | |
| 85379 | <1% | 1,698 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,574 | $6K |
| 82570 | <1% | 1,285 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,340 | $6K |
| 70486 | <1% | 38 | $6K | |
| 70496 | <1% | 100 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 291 | $6K |
| 85652 | <1% | 2,376 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 232 | $5K |
| 82805 | <1% | 409 | $5K | |
| 83540 | <1% | 652 | $4K | |
| 82950 | <1% | 624 | $4K | |
| 76775 | <1% | 57 | $4K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,132 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,788 | $4K |
| 72050 | <1% | 57 | $4K | |
| 84100 | <1% | 1,710 | $4K | |
| 12011 | <1% | 13 | $3K | |
| 76870 | <1% | 70 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 25 | $3K |
| 82951 | <1% | 185 | $3K | |
| 82043 | <1% | 697 | $3K | |
| 83550 | <1% | 459 | $3K | |
| 81025 | <1% | 663 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 609 | $3K |
| 77080 | <1% | 73 | $3K | |
| 83615 | <1% | 474 | $3K | |
| 87210 | <1% | 253 | $3K | |
| 87506 | <1% | 12 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 42 | $3K |
| 97597 | <1% | 55 | $2K | |
| 73590 | <1% | 57 | $2K | |
| 82550 | <1% | 577 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,228 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 977 | $2K |
| 96376 | <1% | 1,302 | $2K | |
| 0272 | <1% | 49 | $2K | |
| 70491 | <1% | 19 | $2K | |
| 10061 | <1% | 13 | $2K | |
| V2632 | Posterior chamber intraocular lens | <1% | 15 | $2K |
| 71101 | <1% | 13 | $2K | |
| 72131 | <1% | 27 | $2K | |
| 86003 | <1% | 13 | $2K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 70 | $2K |
| 96367 | <1% | 74 | $1K | |
| 85007 | <1% | 915 | $1K | |
| 74019 | <1% | 28 | $1K | |
| 87634 | <1% | 21 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 117 | $1K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 393 | $1K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 276 | $991.45 |
| 84153 | <1% | 54 | $954.32 | |
| 80074 | <1% | 13 | $930.41 | |
| 86756 | <1% | 39 | $926.53 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 168 | $895.95 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 241 | $891.31 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $855.41 |
| 87522 | Neg quan hep c or qual rna | <1% | 25 | $831.02 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 70 | $759.90 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 471 | $679.75 |
| 88720 | <1% | 94 | $642.33 | |
| 59025 | Fetal non-stress test | <1% | 32 | $575.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 235 | $535.76 |
| 82270 | <1% | 104 | $494.14 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $494.00 |
| 87147 | <1% | 66 | $487.48 | |
| 73090 | <1% | 12 | $466.56 | |
| 0710 | <1% | 343 | $459.94 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 85 | $459.20 |
| 72170 | <1% | 14 | $435.95 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 231 | $417.40 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 35 | $409.64 |
| 83655 | <1% | 74 | $370.00 | |
| 86780 | <1% | 48 | $349.08 | |
| 86038 | <1% | 101 | $343.69 | |
| 84550 | <1% | 94 | $342.78 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 97 | $324.86 |
| 84481 | <1% | 30 | $320.46 | |
| 87400 | <1% | 20 | $231.60 | |
| 83001 | <1% | 25 | $226.94 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 13 | $218.52 |
| 84156 | <1% | 55 | $184.01 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 41 | $168.24 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 70 | $142.68 |
| 82248 | <1% | 17 | $142.46 | |
| 82247 | <1% | 15 | $122.76 | |
| 82670 | <1% | 12 | $111.20 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 19 | $106.94 |
| 76376 | <1% | 55 | $99.88 | |
| 82140 | <1% | 40 | $96.70 | |
| 84403 | <1% | 15 | $87.00 | |
| 85018 | <1% | 44 | $73.45 | |
| 86431 | <1% | 13 | $70.87 | |
| 80076 | <1% | 12 | $61.20 | |
| 82565 | <1% | 13 | $57.85 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 14 | $55.30 |
| 87081 | <1% | 12 | $39.33 | |
| 82009 | <1% | 53 | $33.11 | |
| 84132 | <1% | 14 | $20.93 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 50 | $9.93 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 24 | $2.12 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 127 | $0.00 |
| 0636 | 0% | 204 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 15 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 38 | $0.00 |
| 99001 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Oxnard, CA | $96.24M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.